Challenges in Amplicon-Based DNA NGS Identification of MET Exon 14 Skipping Events in Non-Small Cell Lung Cancers
<b>Introduction:</b> <i>MET</i> Exon 14 skipping alterations are drivers of non-small cell lung carcinoma (NSCLC) with responses to tyrosine kinase inhibitors. Amplicon-based DNA NGS assays (DNA NGSs) for the detection of <i>MET</i>ex14 skipping can yield false-ne...
Saved in:
| Main Authors: | Magdalena Jurkiewicz, Raymond Yeh, Catherine A. Shu, Susan J. Hsiao, Mahesh M. Mansukhani, Anjali Saqi, Helen Fernandes |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-02-01
|
| Series: | Journal of Molecular Pathology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-5261/6/1/5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ensartinib for advanced or metastatic non-small-cell lung cancer with MET exon 14 skipping mutations (EMBRACE): a multi-center, single-arm, phase 2 trialResearch in context
by: Yang Xia, et al.
Published: (2025-03-01) -
Successful Tepotinib Treatment in MET Exon 14 Skipping Mutation‐Positive Lung Adenocarcinoma With Idiopathic Pulmonary Fibrosis Through Nintedanib Combination
by: Yoshiki Kato, et al.
Published: (2025-06-01) -
MET exon 14 skipping mutations in non-small-cell lung cancer a 3 years screening experience
by: R. Ben Dhiab, et al.
Published: (2025-06-01) -
Case Report: A novel MET exon 14 skipping mutation after EGFR-TKI resistance in advanced lung adenocarcinoma and sustained clinical response to savolitinib
by: Yinyin Xue, et al.
Published: (2025-03-01) -
MET Exon 14 Skipping Mutations in Lung Cancer: Clinical–Pathological Characteristics and Immune Microenvironment
by: Qianqian Xue, et al.
Published: (2025-07-01)